Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 7:38 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 2,287 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Fasted State Clear all

Conditions: Prostate Cancer, Prostate Cancer Metastatic
Interventions: Fasting, Ketone Supplementation; Behavioral · Dietary Supplement
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older · Male only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Gastric Ultrasound, Glucagon-like Peptide 1, Point of Care Ultrasound
Interventions: Gastric Ultrasound Exam; Other
Lead sponsor: Hospital for Special Surgery, New York; Other
Eligibility: 18 Years to 99 Years
Enrollment: 354 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 7
States / cities: Washington D.C., District of Columbia • Jacksonville, Florida • Albany, New York + 2 more

Conditions: Drug Interactions, Neoplasms
Interventions: GSK525762 Besylate Tablets, Itraconazole 200 mg, Rifampicin 300 mg; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 70 Years · Female only
Enrollment: 29 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Fundamental Adaptive Skills Training, Relaxation and Mindfulness Training
Interventions: Fundamental Adaptive Skills Training, Relaxation and Mindfulness Training; Behavioral
Lead sponsor: Florida State University; Other
Eligibility: 18 Years and older
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Tallahassee, Florida

Conditions: Healthy
Interventions: Lamotrigine Tablets 25 mg, Lamictal® Tablets 25 mg; Drug
Lead sponsor: Mylan Pharmaceuticals Inc; Industry
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004
U.S. locations: 1
States / cities: Morgantown, West Virginia

Conditions: Acute Myeloid Leukemia
Interventions: HC-7366; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Healthy
Interventions: Fluoxetine Hydrochloride, PROZAC WEEKLY®; Drug
Lead sponsor: Teva Pharmaceuticals USA; Industry
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2001
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Obesity, Overweight, Intermittent Fasting
Interventions: 3 day caloric restriction/metabolic reset; Dietary Supplement
Lead sponsor: Skidmore College; Other
Eligibility: 25 Years to 65 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Saratoga Springs, New York

Conditions: Adv Solid Malig - H&N SCC, ATM Pro / Def NSCLC, Gastric, Breast and Ovarian Cancer
Interventions: Administration of ceralasertib, Administration of ceralasertib in combination with olaparib, Administation of ceralasertib in combination with durvalumab, Administration of ceralasertib monotherapy, Administration of ceralasertib and olaparib, Administration of ceralasertib and durvalumab, Administration of ceralasertib in combination with AZD5305, Administration of ceralasertib in combination with carboplatin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 358 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2026
U.S. locations: 8
States / cities: Duarte, California • Irvine, California • Los Angeles, California + 4 more

Conditions: Nonhematologic Malignancies, Lymphoma
Interventions: Ixazomib 2.5 mg, Ixazomib 4 mg Capsule A, Ixazomib 4 mg Capsule B, Ketoconazole, Rifampin, Clarithromycin; Drug
Lead sponsor: Millennium Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Opioid-related Disorders
Interventions: BUP_FAST, Referral to treatment; Behavioral
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Fasting, Delayed Gastric Emptying, Aspiration Pneumonia, Respiratory Aspiration of Gastric Content
Interventions: Gastric Ultrasound Baseline Scans, Acetaminophen Absorption Test (AAT), Gastric Ultrasound Serial Scans; Diagnostic Test
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 2 Years to 18 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Sudden Cardiac Death
Interventions: Ovatio VR 6250 or DR6550; Device
Lead sponsor: LivaNova; Industry
Eligibility: Not listed
Enrollment: 198 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 7
States / cities: Sheffield, Alabama • Tarzana, California • Atlanta, Georgia + 4 more

Conditions: Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Interventions: Ren-Nu and KetoCitra; Dietary Supplement
Lead sponsor: Richard Fatica; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Alzheimer Disease, Dementia
Interventions: BMS-984923; Drug
Lead sponsor: Allyx Therapeutics; Industry
Eligibility: 50 Years to 80 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: West Bend, Wisconsin

Conditions: Obesity, Metabolic Syndrome
Interventions: Metabolic flexibility in the fasted state, Metabolic flexibility in euglycemic-hyperinsulinemic clamp, Metabolic flexibility in the metabolic chamber; Diagnostic Test · Other
Lead sponsor: Pennington Biomedical Research Center; Other
Eligibility: 20 Years to 65 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Baton Rouge, Louisiana

Conditions: Healthy
Interventions: Merestinib; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Daytona Beach, Florida

Conditions: Type 2 Diabetes Mellitus
Interventions: Bexagliflozin; Drug
Lead sponsor: Theracos; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Lakewood, Colorado

Conditions: Advanced Solid Malignancies
Interventions: CT7001, Fulvestrant; Drug
Lead sponsor: Carrick Therapeutics Limited; Industry
Eligibility: 18 Years and older
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 12
States / cities: Tucson, Arizona • Beverly Hills, California • Tampa, Florida + 9 more

Conditions: Healthy
Interventions: Zaleplon 10 mg Capsules, Sonata® 10 mg Capsules; Drug
Lead sponsor: Teva Pharmaceuticals USA; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Human Gastrointestinal Physiology Data
Interventions: Single dose of ibuprofen (800 mg tablet), Pulmocare, two 8.0 oz (236.6 mL) cans; Drug · Dietary Supplement
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years to 55 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: SpO2 (Peripheral Oxygen Saturation) Measurement Validation
Interventions: No Intervention; Device
Lead sponsor: Philips Clinical & Medical Affairs Global; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Louisville, Colorado

Conditions: Type 1 Diabetes Mellitus
Interventions: HOE901-U300 (Insulin glargine new formulation), Lantus (Insulin glargine); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 549 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 82
States / cities: Chandler, Arizona • Little Rock, Arkansas • Bell Gardens, California + 71 more

Conditions: Bioavailability
Interventions: Risedronate; Drug
Lead sponsor: Warner Chilcott; Industry
Eligibility: 40 Years to 70 Years · Female only
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 3
States / cities: Fort Myers, Florida • Miramar, Florida • Austin, Texas

Search by objective public record fields.

7-Days Water-Only Fasting or Ketone Supplementation Trial in Prostate Cancer

Gastric Ultrasound Assessment for Patients Taking GLP1 Agonists

A Cross-over Study to Evaluate the Effect of Itraconazole and Rifampicin on the Pharmacokinetics (PK) of GSK525762 in Healthy Female Subjects of Non Child Bearing Potential

The Fundamental Adaptive Skills Training

Fasting Study of Lamotrigine Tablets 25 mg to Lamictal® Tablets 25 mg

Phase I Study of HC-7366 for Acute Myeloid Leukemia

90 mg Fluoxetine Hydrochloride Capsules Under Non-Fasting Conditions

The Acute Effects of Caloric Restriction on Anthropometrics, Metabolism, and Cardiovascular Health in Overweight Adults

Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents

Pharmacokinetics Study of Oral IXAZOMIB in Participants With Advanced Nonhematologic Malignancies or Lymphoma

BUPrenorphine Facilitated Access and Supportive Treatment --AIM 3

Gastric Assessment of Pediatric Patients Undergoing Surgery

Predictive Risk Stratification Through T Variability in ICD Patients Without Pacing Indications

Metabolic Impacts of Ren-Nu: A Dietary Program for Polycystic Kidney Disease

Food Effect Study of BMS-984923 in Healthy Older Adult Volunteers

Impact of Metabolic Flexibility on Changes in Metabolic Health

A Study of Merestinib (LY2801653) in Healthy Participants

Study to Evaluate the Effects of a High-Fat Meal on Bexagliflozin in Healthy Subjects

Modular Study to Evaluate CT7001 Alone in Cancer Patients With Advanced Malignancies

Zaleplon 10mg Capsules Under Fasting Conditions

Modernization of in vivo-in Vitro Oral Bioperformance Prediction and Assessment

Philps FAST2022 picoSAT Pulse Oximetry Desaturation Study

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 1 Diabetes Mellitus

Assess the Influence of a High-fat Meal on the Relative Bioavailability Of Two Formulations of Risedronate